TEVA vs. MRK
Compare and contrast key facts about Teva Pharmaceutical Industries Limited (TEVA) and Merck & Co., Inc. (MRK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: TEVA or MRK.
Correlation
The correlation between TEVA and MRK is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
TEVA vs. MRK - Performance Comparison
Loading data...
Key characteristics
TEVA:
0.12
MRK:
-1.52
TEVA:
1.09
MRK:
-2.13
TEVA:
1.14
MRK:
0.72
TEVA:
0.26
MRK:
-0.96
TEVA:
1.24
MRK:
-1.76
TEVA:
17.21%
MRK:
22.68%
TEVA:
47.40%
MRK:
26.31%
TEVA:
-90.80%
MRK:
-68.62%
TEVA:
-74.73%
MRK:
-41.52%
Fundamentals
TEVA:
$18.80B
MRK:
$208.01B
TEVA:
-$1.45
MRK:
$6.88
TEVA:
1.29
MRK:
0.76
TEVA:
1.12
MRK:
3.25
TEVA:
3.46
MRK:
4.52
TEVA:
$16.61B
MRK:
$63.92B
TEVA:
$8.17B
MRK:
$51.75B
TEVA:
$725.00M
MRK:
$27.30B
Returns By Period
The year-to-date returns for both investments are quite close, with TEVA having a -23.19% return and MRK slightly higher at -22.97%. Over the past 10 years, TEVA has underperformed MRK with an annualized return of -11.34%, while MRK has yielded a comparatively higher 6.17% annualized return.
TEVA
-23.19%
19.56%
-1.05%
5.81%
8.46%
-11.34%
MRK
-22.97%
-7.25%
-24.95%
-39.94%
3.98%
6.17%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
TEVA vs. MRK — Risk-Adjusted Performance Rank
TEVA
MRK
TEVA vs. MRK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Teva Pharmaceutical Industries Limited (TEVA) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
TEVA vs. MRK - Dividend Comparison
TEVA has not paid dividends to shareholders, while MRK's dividend yield for the trailing twelve months is around 4.16%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
TEVA Teva Pharmaceutical Industries Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 4.49% | 3.75% | 2.07% | 2.38% |
MRK Merck & Co., Inc. | 4.16% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% | 3.12% |
Drawdowns
TEVA vs. MRK - Drawdown Comparison
The maximum TEVA drawdown since its inception was -90.80%, which is greater than MRK's maximum drawdown of -68.62%. Use the drawdown chart below to compare losses from any high point for TEVA and MRK. For additional features, visit the drawdowns tool.
Loading data...
Volatility
TEVA vs. MRK - Volatility Comparison
Loading data...
Financials
TEVA vs. MRK - Financials Comparison
This section allows you to compare key financial metrics between Teva Pharmaceutical Industries Limited and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TEVA vs. MRK - Profitability Comparison
TEVA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Teva Pharmaceutical Industries Limited reported a gross profit of 1.88B and revenue of 3.89B. Therefore, the gross margin over that period was 48.2%.
MRK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Merck & Co., Inc. reported a gross profit of 12.11B and revenue of 15.53B. Therefore, the gross margin over that period was 78.0%.
TEVA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Teva Pharmaceutical Industries Limited reported an operating income of 706.00M and revenue of 3.89B, resulting in an operating margin of 18.1%.
MRK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Merck & Co., Inc. reported an operating income of 5.94B and revenue of 15.53B, resulting in an operating margin of 38.2%.
TEVA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Teva Pharmaceutical Industries Limited reported a net income of 214.00M and revenue of 3.89B, resulting in a net margin of 5.5%.
MRK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Merck & Co., Inc. reported a net income of 5.08B and revenue of 15.53B, resulting in a net margin of 32.7%.